Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: A decision analysis

American Journal of Medicine

Volumn 116, Issue 9, 2004, Pages 621-629

  Choi, Hyon K ^a,c   Seeger, John D ^b,d   Kuntz, Karen M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Epidemiology ^*  (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Ingenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; ROFECOXIB;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POPULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

AGED; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DECISION SUPPORT TECHNIQUES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; QUALITY OF LIFE; SULFONES; TIME FACTORS;

EID: 1842850716     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.050     Document Type: Article

References (48)

1. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 341:1999;1397-1399.
2. Peterson W.L., Cryer B. COX-1-sparing NSAIDS - is the enthusiasm justified? JAMA. 282:1999;1961-1963.
3. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
4. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 343:2000;1520-1528.
5. FDA Advisory Committee. Cardiovascular safety review of rofecoxib. 2001;Food and Drug Administration, Rockville, Maryland. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. Accessed December 5, 2002.
6. Konstam M.A., Weir M.R., Reicin A., et al. Thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 104:2001;2280-2288.
7. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 105:(suppl):1998;31S-38S.
8. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249.
9. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 115:1991;787-796.
10. Maetzel A., Ferraz M.B., Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 41:1998;16-25.
11. Griffin M.R., Ray W.A., Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 109:1988;359-363.
12. Somerville K., Faulkner G., Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1:1986;462-464.
13. Fries J.F., Miller S.R., Spitz P.W., Williams C.A., Hubert H.B., Bloch D.A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 96:1989;647-655.
14. Henry D.A., Johnston A., Dobson A., Duggan J. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. BMJ. 295:1987;1227-1229.
15. Mitchell D.M., Spitz P.W., Young D.Y., Bloch D.A., McShane D.J., Fries J.F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 29:1986;706-714.
16. American Heart Association. 2002 Heart and Stroke Statistical Update. 2001;12-13 American Heart Association, Dallas, Texas.
17. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 339:1998;861-867.
18. Anderson K.M., Odell P.M., Wilson P.W., Kannel W.B. Cardiovascular disease risk profiles. Am Heart J. 121:1991;293-298.
19. Anderson K.M., Wilson P.W., Odell P.M., Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation. 83:1991;356-362.
20. Goldberg R.J., McCormick D., Gurwitz J.H., Yarzebski J., Lessard D., Gore J.M. Age-related trends in short- and long-term survival after acute myocardial infarction a 20-year population-based perspective (1975-1995). Am J Cardiol. 82:1998;1311-1317.
21. Kuntz K.M., Weinstein M.C. Life expectancy biases in clinical decision modeling. Med Decis Making. 15:1995;158-169.
22. Wolfe F., Zwillich S.H. The long-term outcomes of rheumatoid arthritis a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 41:1998;1072-1082.
23. Fryback D.G., Dasbach E.J., Klein R., et al. The Beaver Dam Health Outcomes Study initial catalog of health-state quality factors. Med Decis Making. 13:1993;89-102.
24. McGovern P.G., Pankow J.S., Shahar E., et al. Recent trends in acute coronary heart disease - mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med. 334:1996;884-890.
25. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 28:1987;527-532.
26. Pounder R. Silent peptic ulceration deadly silence or golden silence? Gastroenterology. 96:1989;626-631.
27. Edelson J.T., Tosteson A.N., Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 264:1990;41-47.
28. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 338:1998;727-734.
29. Doubilet P., Begg C.B., Weinstein M.C., Braun P., McNeil B.J. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 5:1985;157-177.
30. Spiegel B.M., Targownik L., Dulai G.S., Gralnek I.M. The costeffectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 138:2003;795-806.
31. Wright J.C., Weinstein M.C. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 339:1998;380-386.
32. Hernandez-Diaz S., Garcia-Rodriguez L.A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 110:(suppl):2001;20S-27S.
33. Mutru O., Laakso M., Isomaki H., Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ. 290:1985;1797-1799.
34. Isomaki H.A., Mutru O., Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol. 4:1975;205-208.
35. Symmons D.P., Jones M.A., Scott D.L., Prior P. Long-term mortality outcome in patients with rheumatoid arthritis early presenters continue to do well. J Rheumatol. 25:1998;1072-1077.
36. Wallberg-Jonsson S., Ohman M.L., Dahlqvist S.R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 24:1997;445-451.
37. Park Y.B., Choi H.K., Kim M.Y., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis a prospective study. Am J Med. 113:2002;188-193.
38. McEntegart A., Capell H.A., Creran D., Rumley A., Woodward M., Lowe G.D. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 40:2001;640-644.
39. Roubenoff R., Dellaripa P., Nadeau M.R., et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40:1997;718-722.
40. del Rincon I., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44:2001;2737-2746.
41. Hochberg M.C. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol. 19:2001;S15-S22.
42. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284:2000;1247-1255.
43. Hennan J.K., Huang J., Barrett T.D., et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 104:2001;820-825.
44. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
45. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
46. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 334:1996;1435-1439.
47. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
48. Zhang Y.Q., Chaisson C.E., Evans S., Naimark A., Felson D.T. Does radiographic knee osteoarthritis increase mortality in the elderly? Arthritis Rheum. 41:1998;S180.